Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study.
Masahiro YasakaHiroyuki YokotaMichiyasu SuzukiHidesaku AsakuraTeiichi YamaneYukako OgiTakaaki KimotoDaisuke NakayamaPublished in: Cardiology and therapy (2023)
This study is registered with ClinicalTrials.gov (NCT02946931).